Our second, an alpha-emitting actinium-based compound, CLR121-225, or referred to as CLR225. Our OJ emitting radioconjugate product candidate, CLR125, potentially represents the highest level of precision in targeted radiotherapy, with its emissions traveling only a few nanometers.

Aug 14, 2025 / COO / receipt, needs a key / Jared Lancourt, COO | earnings call 2025-08-14 | transcript 78980747-702c-4e7e-924c-3a510d2ac193 | chars 10734-11016 | segment 10